Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses from the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology (NOGGO) Ovarian Cancer Working Group.

Mustea, A., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Reichert, D., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Sehouli, J., 2016.

Ann Oncol 27(suppl_6), 296–312, 867P. doi:10.1093/annonc/mdw374.14

Studie: OTILIA; Indikation: Sonstige; Jahr: 2016; Veranstaltung: ESMO; Journal: Annals of Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com